CommScope Holding Company has priced its IPO of 38,461,537 shares at $18 to $21 per share. CommScope plans on listing the stock on the NASDAQ under the ticker symbol “COMM.” J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch serve as lead underwriters. CommScope is a telecommunications equipment provider. The Carlyle Group has a majority ownership stake in CommScope.
CommScope Holding Company, Inc. has commenced an initial public offering of 38,461,537 shares of its common stock, of which 30,769,230 shares are to be sold by CommScope and 7,692,307 shares are to be sold by an affiliate of The Carlyle Group (the “selling stockholder”). The anticipated initial offering price is between $18.00 and $21.00 per share and the offering is being made pursuant to a registration statement on Form S-1 previously filed with the U.S. Securities and Exchange Commission. The selling stockholder has also granted the underwriters a 30-day option to purchase up to an additional 5,769,230 shares of CommScope’s common stock. CommScope will not receive proceeds from any exercise by the underwriters of their option to purchase additional shares. CommScope has applied for listing of its common stock on the NASDAQ Global Select Market under the ticker symbol “COMM.”
CommScope intends to use the net proceeds it receives from the offering, plus cash on hand, to redeem a portion of CommScope, Inc.’s 8.25% Senior Notes due 2019 and to pay related premiums, expenses and accrued interest.
J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch are lead book-running managers for the proposed initial public offering. Additional book-running managers are Barclays, Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co., Jefferies, Morgan Stanley & Co. LLC, RBC Capital Markets and Wells Fargo Securities. Co-Managers are Allen & Company LLC, Evercore, Raymond James, Mizuho Securities, SMBC Nikko and Drexel Hamilton.
Vital Therapies has filed for an IPO. The number of shares to be offered and pricing terms have yet to be decided. Credit Suisse Securities and William Blair & Company, will serve as lead underwriters. Based in San Diego, Calif., Vital Therapies is a provider of cell-based therapy solutions that treat acute liver failure
SAN DIEGO, CA–(Marketwired – Oct 11, 2013) – Vital Therapies, Inc., a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.
Credit Suisse Securities (USA) LLC and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. Cowen and Company, LLC and Canaccord Genuity Inc. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, Telephone: (800) 221-1037, Email: NEWYORK.PROSPECTUS@CREDIT-SUISSE.COM; or from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, Telephone: (800) 621-0687.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure. The company’s lead product-candidate, ELAD, is an extracorporeal bio-artificial liver currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California.
Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.